Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · see citing works

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

<tt>edgeR</tt> : a Bioconductor package for differential expression analysis of digital gene expression data

Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364 · see citing works

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Cancer Statistics, 2017.

Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Robust enumeration of cell subsets from tissue expression profiles

Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 12,116 · see citing works

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1× · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works

TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells

Li, T., Fan, J., Wang, B., Traugh, N. C., Chen, Q., Liu, J. S., Li, B., & Liu, X. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0307 · Cited by 5,914 · see citing works

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,684 · see citing works

Molecular and cellular insights into T cell exhaustion

Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · see citing works

Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer

Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350 · see citing works

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works

Tumor-Associated Macrophages: From Mechanisms to Therapy

Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · see citing works

Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis

Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R., Côme, C., Savagner, P., Gitelman, I., Richardson, A. L., & Weinberg, R. A. (2004) · Cell · doi:10.1016/j.cell.2004.06.006 · Cited by 3,856 · see citing works

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew‐Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,852 · see citing works

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,414 · see citing works

Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?

Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121 · see citing works

The prognostic landscape of genes and infiltrating immune cells across human cancers

Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,097 · see citing works

Trastuzumab — Mechanism of Action and Use in Clinical Practice

Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,592 · see citing works

T cell exclusion, immune privilege, and the tumor microenvironment

Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,494 · see citing works

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345 · see citing works

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2

Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes &amp; Development · doi:10.1101/gad.1640608 · Cited by 2,272 · see citing works

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

Cristescu, R., Lee, J., Nebozhyn, M., Kim, K.-M., Ting, J. C., Wong, S. S., Liu, J., Yue, Y. G., Wang, J., Yu, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3850 · Cited by 2,223 · see citing works

Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment

Azizi, E., Carr, A. J., Plitas, G., Cornish, A. E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.060 · Cited by 1,976 · see citing works

Molecular requirements for epithelial–mesenchymal transition during tumor progression

Huber, M. A., Kraut, N., & Beug, H. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.08.001 · Cited by 1,813 · see citing works

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb‐Esfahani, S., Kronenwett, R., Hanusch, C. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,751 · see citing works

A reciprocal repression between ZEB1 and members of the miR‐200 family promotes EMT and invasion in cancer cells

Burk, U., Schubert, J., Wellner, U. F., Schmalhofer, O., Vincan, E., Spaderna, S., & Brabletz, T. (2008) · EMBO Reports · doi:10.1038/embor.2008.74 · Cited by 1,722 · see citing works

The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs

Wellner, U. F., Schubert, J., Burk, U., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., Vannier, C., Darling, D. S., Hausen, A. Z., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1998 · Cited by 1,686 · see citing works

The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2

Korpal, M., Lee, E. S., Hu, G., & Kang, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c800074200 · Cited by 1,642 · see citing works

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477 · see citing works

The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion.

Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven, L. V., Bruyneel, E., Mareel, M., Huylebroeck, D., & van Roy, F. (2001) · Molecules and Cells · doi:10.1016/s1097-2765(01)00260-x · Cited by 1,464 · see citing works

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

Creighton, C. J., Li, X., Landis, M. D., Dixon, J. M., Neumeister, V. M., Sjolund, A. B., Rimm, D. L., Wong, H. H., Rodriguez, A. A., Herschkowitz, J. I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905718106 · Cited by 1,414 · see citing works

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404 · see citing works

PD-L1 Expression in Triple-Negative Breast Cancer

Mittendorf, E. A., Philips, A. V., Meric‐Bernstam, F., Qiao, N., Wu, Y., Harrington, S. M., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akçakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,394 · see citing works

Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer

Mahmoud, S., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367 · see citing works

Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade

Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · see citing works

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224 · see citing works

Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells

Shimono, Y., Zabala, M., Cho, R. W., Lobo, N. A., Dalerba, P. D., Qian, D., Diehn, M., Liu, H., Panula, S., Chiao, E. T., et al. (2009) · Cell · doi:10.1016/j.cell.2009.07.011 · Cited by 1,205 · see citing works

A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition.

Bracken, C., Gregory, P. A., Kolesnikoff, N., Bert, A., Wang, J., Shannon, M., & Goodall, G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1942 · Cited by 1,099 · see citing works

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059 · see citing works

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes

Taube, J. H., Herschkowitz, J. I., Komurov, K., Zhou, A. Y., Gupta, S. K., Yang, J., Hartwell, K. A., Önder, T. T., Gupta, P. B., Evans, K. W., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004900107 · Cited by 1,041 · see citing works

TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression

Yang, L., Pang, Y., & Moses, H. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.002 · Cited by 1,023 · see citing works

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y., Byers, L. A., Zhang, X., Yi, X., Dwyer, D. W., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 972 · see citing works

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890 · see citing works

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 879 · see citing works

Breast Cancer Immunotherapy: Facts and Hopes

Emens, L. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3001 · Cited by 876 · see citing works

Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule

Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B., Cantoni, C., Grassi, J., Marcenaro, S., Reymond, N., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030788 · Cited by 874 · see citing works

Acquired resistance to TKIs in solid tumours: learning from lung cancer

Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862 · see citing works

Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function

Condamine, T., & Gabrilovich, D. I. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.10.002 · Cited by 846 · see citing works

DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells

Eger, A., Aigner, K., Sonderegger, S., Dampier, B., Oehler, S., Schreiber, M., Berx, G., Cano, A., Beug, H., & Foisner, R. (2005) · Oncogene · doi:10.1038/sj.onc.1208429 · Cited by 808 · see citing works

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy517 · Cited by 807 · see citing works

Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment

Kim, J., & Bae, J. (2016) · Mediators of Inflammation · doi:10.1155/2016/6058147 · Cited by 803 · see citing works

Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients

Ali, H. R., Provenzano, E., Dawson, S., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, L., Dunn, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu191 · Cited by 773 · see citing works

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Dirix, L. Y., Takács, I., Jérusalem, G., Nikolinakos, P. G., Arkenau, H., Forero, A., Boccia, R. V., Lippman, M. E., Somer, R. A., Šmakal, M., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 748 · see citing works

Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer

Reck, M., & Rabe, K. F. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1703413 · Cited by 725 · see citing works

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676 · see citing works

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

Farmer, P. J., Bonnefoi, H. R., Anderle, P., Cameron, D., Wirapati, P., Becette, V., André, S., Piccart, M. J., Campone, M., Brain, E. G. C., et al. (2009) · Nature Medicine · doi:10.1038/nm.1908 · Cited by 618 · see citing works

Mesenchyme Forkhead 1 ( FOXC2 ) plays a key role in metastasis and is associated with aggressive basal-like breast cancers

Mani, S. A., Yang, J., Brooks, M. W., Schwaninger, G., Zhou, A. Y., Miura, N., Kutok, J. L., Hartwell, K. A., Richardson, A. L., & Weinberg, R. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703900104 · Cited by 576 · see citing works

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536 · see citing works

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

Mak, M. P., Tong, P., Diao, L., Cardnell, R. J., Gibbons, D. L., William, W. N., Skoulidis, F., Parra, E. R., Rodriguez‐Canales, J., Wistuba, I. I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0876 · Cited by 526 · see citing works

Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expressionPreprint

Gibbons, D. L., Lin, W., Creighton, C. J., Rizvi, Z. H., Gregory, P. A., Goodall, G. J., Thilaganathan, N., Du, L., Zhang, Y., Pertsemlidis, A., et al. (2009) · Genes & Development · doi:10.1101/gad.1820209 · Cited by 516 · see citing works

MicroRNAs as regulators of epithelial-mesenchymal transition

Gregory, P. A., Bracken, C. P., Bert, A. G., & Goodall, G. J. (2008) · Cell Cycle · doi:10.4161/cc.7.20.6851 · Cited by 506 · see citing works

Cytotoxic T Cells

Andersen, M. H., Schrama, D., Straten, P. T., & Becker, J. C. (2005) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700001 · Cited by 492 · see citing works

An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer

Teschendorff, A. E., Miremadi, A., Pinder, S. E., Ellis, I. O., & Caldas, C. (2007) · Genome biology · doi:10.1186/gb-2007-8-8-r157 · Cited by 492 · see citing works

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers

Rody, A., Holtrich, U., Pusztai, L., Liedtke, C., Gaetje, R., Ruckhaeberle, E., Solbach, C., Hanker, L., Ahr, A., Metzler, D., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2234 · Cited by 460 · see citing works

Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

Lou, Y., Diao, L., Parra, E. R., Denning, W. L., Chen, L., Fan, Y. H., Byers, L. A., Wang, J., Papadimitrakopoulou, V. A., Behrens, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1434 · Cited by 439 · see citing works

CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer

Liu, S., Lachapelle, J., Leung, S. C. Y., Gao, D., Foulkes, W. D., & Nielsen, T. O. (2012) · Breast Cancer Research · doi:10.1186/bcr3148 · Cited by 437 · see citing works

New insights into the role of <scp>EMT</scp> in tumor immune escape

Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414 · see citing works

Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing

Casasent, A. K., Schalck, A., Gao, R., Sei, E., Long, A., Pangburn, W., Casasent, T., Meric-Bernstam, F., Edgerton, M. E., & Navin, N. E. (2018) · Cell · doi:10.1016/j.cell.2017.12.007 · Cited by 411 · see citing works

Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas

Dongre, A., Rashidian, M., Reinhardt, F., Bagnato, A., Keckesova, Z., Ploegh, H. L., & Weinberg, R. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3292 · Cited by 395 · see citing works

Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression

Xu, C., Brainson, C. F., Koyama, S., Wu, H., Zhao, Y., Chen, Z., Herter-Sprie, G. S., Akbay, E. A., Tchaicha, J. H., Altabef, A. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.033 · Cited by 394 · see citing works

Immunogenic effects of chemotherapy-induced tumor cell death

Wang, Y., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 316 · see citing works

Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion

Dong, P., Xiong, Y., Yue, J., Hanley, S. J. B., & Watari, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00386 · Cited by 312 · see citing works

A MicroRNA Expression Signature for Cervical Cancer Prognosis

Hu, X., Schwarz, J. K., Lewis, J. S., Huettner, P. C., Rader, J. S., Deasy, J. O., Grigsby, P. W., & Wang, X. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3289 · Cited by 310 · see citing works

Loss of miR-200c Expression Induces an Aggressive, Invasive, and Chemoresistant Phenotype in Non–Small Cell Lung Cancer

Ceppi, P., Mudduluru, G., Kumarswamy, R., Rapa, I., Scagliotti, G. V., Papotti, M. G., & Allgayer, H. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0052 · Cited by 304 · see citing works

Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis

Akalay, I., Janji, B., Hasmim, M., Noman, M. Z., André, F., de Crémoux, P., Bertheau, P., Badoual, C., Vielh, P. R., Larsen, A. K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2432 · Cited by 302 · see citing works

Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer

Iglesia, M. D., Vincent, B. G., Parker, J. S., Hoadley, K. A., Carey, L., Perou, C. M., & Serody, J. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3368 · Cited by 276 · see citing works

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 275 · see citing works

Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)

Chae, Y. K., Chang, S., Ko, T., Anker, J. F., Agte, S., Iams, W. T., Choi, W. M., Lee, K., & Cruz, M. R. D. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-21061-1 · Cited by 252 · see citing works

Myeloid‐derived suppressor cell activation by combined LPS and IFN‐γ treatment impairs DC development

Greifenberg, V., Ribechini, E., Rößner, S., & Lutz, M. B. (2009) · European Journal of Immunology · doi:10.1002/eji.200939486 · Cited by 241 · see citing works

Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric

George, J. T., Jolly, M. K., Xu, S., Somarelli, J. A., & Levine, H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3521 · Cited by 240 · see citing works

Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer

García-Martínez, E., Gil, G. L., Benito, A. C., González-Billalabeitia, E., Conesa, M. V., García, T., García-Garre, E., Vicente, V., & de la Peña, F. A. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0488-5 · Cited by 236 · see citing works

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer

Stewart, C. A., Tong, P., Cardnell, R. J., Sen, T., Li, L., Gay, C. M., Masrorpour, F., Fan, Y. H., Bara, R. O., Feng, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15338 · Cited by 227 · see citing works

Tumor Cell–Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells

Svoronos, N., Perales‐Puchalt, A., Allegrezza, M. J., Rutkowski, M. R., Payne, K. K., Tesone, A. J., Nguyen, J. M., Curiel, T. J., Cadungog, M. G., Singhal, S. K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0502 · Cited by 218 · see citing works

Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer

Dine, J. L., Gordon, R., Shames, Y., Kasler, M. K., & Barton‐Burke, M. (2017) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/apjon.apjon_4_17 · Cited by 217 · see citing works

Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation

Welte, T., Kim, I. S., Tian, L. H., Gao, X., Wang, H., Li, J., Holdman, X. B., Herschkowitz, J. I., Pond, A. C., Xie, G., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3355 · Cited by 214 · see citing works

Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

Perez, E. A., Thompson, E. A., Ballman, K. V., Anderson, S. K., Asmann, Y. W., Kalari, K. R., Eckel‐Passow, J. E., Dueck, A. C., Tenner, K., Jen, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.6298 · Cited by 203 · see citing works

Expression of PD-L1 and prognosis in breast cancer: a meta-analysis

Zhang, M., Sun, H., Zhao, S., Wang, Y., Pu, H., Wang, Y., & Zhang, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.15532 · Cited by 201 · see citing works

PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma

Asgarova, A., Asgarov, K., Godet, Y., Peixoto, P., Nadaradjane, A., Boyer‐Guittaut, M., Galaine, J., Guenat, D., Mougey, V., Perrard, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1423170 · Cited by 198 · see citing works

The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200–dependent pathway in mice

Yang, Y., Ahn, Y., Gibbons, D. L., Zang, Y., Lin, W., Thilaganathan, N., Alvarez, C. A., Moreira, D. C., Creighton, C. J., Gregory, P. A., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42579 · Cited by 196 · see citing works

Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis.

Sethi, S. N., Macoska, J. A., Chen, W., & Sarkar, F. H. (2010) · PubMed Central · Cited by 192 · see citing works

Twist1 Induces CCL2 and Recruits Macrophages to Promote Angiogenesis

Low-Marchelli, J. M., Ardi, V. C., Vizcarra, E. A., van Rooijen, N., Quigley, J. P., & Yang, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-0653 · Cited by 192 · see citing works

Acetylation of Snail Modulates the Cytokinome of Cancer Cells to Enhance the Recruitment of Macrophages

Hsu, D. S., Wang, H.-J., Tai, S., Chou, C.-H., Hsieh, C.-H., Chiu, P.-H., Chen, N., & Yang, M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.002 · Cited by 191 · see citing works

Mechanisms of the Epithelial–Mesenchymal Transition and Tumor Microenvironment in Helicobacter pylori-Induced Gastric Cancer

Baj, J., Korona‐Głowniak, I., Forma, A., Maani, A., Sitarz, R., Rahnama, M., Radzikowska, E., & Portincasa, P. (2020) · Cells · doi:10.3390/cells9041055 · Cited by 173 · see citing works

Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes

Forero, A., Li, Y., Chen, D., Grizzle, W. E., Updike, K. L., Merz, N. D., Downs-Kelly, E. P., Burwell, T. C., Vaklavas, C., Buchsbaum, D. J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0243 · Cited by 170 · see citing works

A signature of immune function genes associated with recurrence-free survival in breast cancer patients

Ascierto, M. L., Kmieciak, M., Idowu, M. O., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1470-x · Cited by 167 · see citing works

PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung

Kim, S., Koh, J., Kim, M., Kwon, D., Go, H., Kim, Y. A., Jeon, Y. K., & Chung, D. H. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.07.007 · Cited by 166 · see citing works

ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression

Ahn, Y., Gibbons, D. L., Chakravarti, D., Creighton, C. J., Rizvi, Z. H., Adams, H. P., Pertsemlidis, A., Gregory, P. A., Wright, J. A., Goodall, G. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63608 · Cited by 157 · see citing works

Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra‐tumour genetic heterogeneity and clonal selection

Hernández, L., Wilkerson, P. M., Lambros, M. B. K., et al. (2012) · The Journal of Pathology · doi:10.1002/path.3990 · Cited by 151 · see citing works

Epithelial-mesenchymal transition leads to NK cell–mediated metastasis-specific immunosurveillance in lung cancer

Chockley, P. J., Chen, J., Chen, G., Beer, D. G., Standiford, T. J., & Keshamouni, V. G. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97611 · Cited by 140 · see citing works

Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition

Knutson, K. L., Lu, H., Stone, B. C., Reiman, J. M., Behrens, M. D., Prosperi, C., Gad, E. A., Smorlesi, A., & Disis, M. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1526 · Cited by 136 · see citing works

Targets of the Tumor Suppressor miR-200 in Regulation of the Epithelial–Mesenchymal Transition in Cancer

Schliekelman, M. J., Gibbons, D. L., Faça, V. M., Creighton, C. J., Rizvi, Z. H., Zhang, Q. H., Wong, C., Wang, H., Ungewiss, C., Ahn, Y., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0964 · Cited by 136 · see citing works

A Multi-Cancer Mesenchymal Transition Gene Expression Signature Is Associated with Prolonged Time to Recurrence in Glioblastoma

Cheng, W., Kandel, J. J., Yamashiro, D. J., Canoll, P., & Anastassiou, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034705 · Cited by 132 · see citing works

Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.

Adams, S., Schmid, P., Rugo, H. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1008 · Cited by 130 · see citing works

Generation of highly suppressive adaptive CD8+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation

Mahic, M., Henjum, K., Yaqub, S., Bjørnbeth, B. A., Torgersen, K. M., Taskén, K., & Aandahl, E. M. (2008) · European Journal of Immunology · doi:10.1002/eji.200737529 · Cited by 124 · see citing works

Triple negative breast cancer – prognostic role of immune-related factors: a systematic review

Stovgaard, E. S., Nielsen, D. L., Høgdall, E. V. S., & Balslev, E. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1400180 · Cited by 121 · see citing works

Structure of Natural Killer Cell Receptor KLRG1 Bound to E-Cadherin Reveals Basis for MHC-Independent Missing Self Recognition

Li, Y., Hofmann, M., Wang, Q., Teng, L., Chlewicki, L. K., Pircher, H., & Mariuzza, R. A. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.019 · Cited by 115 · see citing works

The crucial role of ZEB2: From development to epithelial‐to‐mesenchymal transition and cancer complexity

Fardi, M., Alivand, M. R., Baradaran, B., Hagh, M. F., & Solali, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28277 · Cited by 114 · see citing works

Prospects for new lung cancer treatments that target EMT signaling

Otsuki, Y., Saya, H., & Arima, Y. (2017) · Developmental Dynamics · doi:10.1002/dvdy.24596 · Cited by 112 · see citing works

The role of CD8 T cells in innate immunity and in antigen non-specific protection

Berg, R. E., & Forman, J. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.03.010 · Cited by 109 · see citing works

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients

Ascierto, M. L., Idowu, M. O., Zhao, Y., Khalak, H. G., Payne, K. K., Wang, X., Dumur, C. I., Bedognetti, D., Tomei, S., Ascierto, P. A., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-145 · Cited by 108 · see citing works

The Role of MicroRNAs in Breast Cancer Stem Cells

Schwarzenbacher, D., Balić, M., & Pichler, M. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140714712 · Cited by 81 · see citing works

The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis

Zhang, L., Liang, Y., Li, S., Zeng, F., Meng, Y., Chen, Z., Liu, S., Tao, Y., & Yu, F. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0989-z · Cited by 73 · see citing works

Macrophages promote the progression of premalignant mammary lesions to invasive cancer

Carron, E. C., Homra, S., Rosenberg, J. N., Coffelt, S. B., Kittrell, F. S., Zhang, Y., Creighton, C. J., Fuqua, S. A. W., Medina, D., & Machado, H. L. (2017) · Oncotarget · doi:10.18632/oncotarget.14913 · Cited by 72 · see citing works

The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL

Ungewiss, C., Rizvi, Z. H., Roybal, J. D., Peng, D. H., Gold, K. A., Shin, D. H., Creighton, C. J., & Gibbons, D. L. (2016) · Scientific Reports · doi:10.1038/srep18652 · Cited by 70 · see citing works

Targeting the programmed cell death-1 pathway in breast and ovarian cancer

Emens, L. A., Kok, M., & Ojalvo, L. S. (2016) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000257 · Cited by 58 · see citing works

TGF β : A player on multiple fronts in the tumor microenvironment

Čaja, F., & Vannucci, L. E. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2014.945667 · Cited by 56 · see citing works

Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients

Markiewicz, A., Topa, J., Nagel, A. C., Skokowski, J., Seroczyńska, B., Stokowy, T., Wełnicka-Jaśkiewicz, M., & Zaczek, A. J. (2019) · Cancers · doi:10.3390/cancers11010059 · Cited by 55 · see citing works

Tumor Plasticity Interferes with Anti-Tumor Immunity

Chouaı̈b, S., Janji, B., Tittarelli, A., Eggermont, A. M. M., & Thiery, J. P. (2014) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2014010183 · Cited by 50 · see citing works

Dual role of immunomodulation by anticancer chemotherapy

Shurin, M. R. (2013) · Nature Medicine · doi:10.1038/nm.3045 · Cited by 47 · see citing works

Targeting CD8 + T-cell Tolerance for Cancer Immunotherapy

Jackson, S. R., Yuan, J., & Teague, R. M. (2014) · Immunotherapy · doi:10.2217/imt.14.51 · Cited by 47 · see citing works

Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer

Ramani, V. C., Lemaire, C. A., Triboulet, M. M., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1182-4 · Cited by 47 · see citing works

Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.

McArthur, H. L., & Page, D. B. (2016) · PubMed · Cited by 46 · see citing works

Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS

Sugio, T., Miyawaki, K., Kato, K., Sasaki, K., Yamada, K., Iqbal, J., Miyamoto, T., Ohshima, K., Maeda, T., Miyoshi, H., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018018754 · Cited by 46 · see citing works

Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer

Kumar, S., Davra, V., Obr, A. E., Geng, K., Wood, T. L., Lorenzo, M. S. D., & Birge, R. B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1376155 · Cited by 44 · see citing works

Gene delivery of TIPE2 inhibits breast cancer development and metastasis via CD8+ T and NK cell-mediated antitumor responses

Zhang, Z., Liu, L., Cao, S., Zhu, Y. Z., & Mei, Q. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.03.007 · Cited by 36 · see citing works

Preliminary mechanisms of regulating PD‑L1 expression in non‑small cell lung cancer during the EMT process

Li, F., Zhu, T., Yue, Y., Zhu, X., Wang, J., & Liang, L. (2018) · Oncology Reports · doi:10.3892/or.2018.6474 · Cited by 33 · see citing works

SIGNATURE: A workbench for gene expression signature analysis

Chang, J. T., Gatza, M. L., Lucas, J. E., Barry, W. T., Vaughn, P., & Nevins, J. R. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-443 · Cited by 32 · see citing works

Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene

Niyomnaitham, S., Parinyanitikul, N., Roothumnong, E., Jinda, W., Samarnthai, N., Atikankul, T., Suktitipat, B., Thongnoppakhun, W., Limwongse, C., & Pithukpakorn, M. (2019) · PeerJ · doi:10.7717/peerj.6501 · Cited by 31 · see citing works

A New Strategy Using ALDHhigh-CD8+T Cells to Inhibit Tumorigenesis

Luo, H., Zeng, C., Fang, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103193 · Cited by 30 · see citing works

Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer

Matteis, S. D., Canale, M., Verlicchi, A., Bronte, G., Delmonte, A., Crinò, L., Martinelli, G., & Ulivi, P. (2019) · Journal of Oncology · doi:10.1155/2019/7475364 · Cited by 27 · see citing works

Repurposing Antiestrogens for Tumor Immunotherapy

Welte, T., Zhang, X. H.-F., & Rosen, J. M. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1308 · Cited by 25 · see citing works

Integrative Radiogenomics Approach for Risk Assessment of Post-Operative Metastasis in Pathological T1 Renal Cell Carcinoma: A Pilot Retrospective Cohort Study

Lee, H. W., Cho, H.-H., Joung, J., Jeon, H. G., Jeong, B. C., Jeon, S. S., Lee, H. M., Nam, D., Park, W., Kim, C. K., et al. (2020) · Cancers · doi:10.3390/cancers12040866 · Cited by 25 · see citing works

EMT in immuno-resistance

Terry, S., & Chouaı̈b, S. (2015) · Oncoscience · doi:10.18632/oncoscience.226 · Cited by 23 · see citing works

The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.

Dye, E. S. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.4.1510 · Cited by 19 · see citing works

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works

HIF-1α inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer

Luo, F., Lu, F.-T., Cao, J.-X., Ma, W.-J., Xia, Z.-F., Zhan, J.-H., Zeng, K.-M., Huang, Y., Zhao, H.-Y., & Zhang, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.027 · Cited by 95 · see citing works

B7H1 Expression and Epithelial-To-Mesenchymal Transition Phenotypes on Colorectal Cancer Stem-Like Cells

Zhi, Y., Mou, Z., Chen, J., He, Y., Dong, H. F., Fu, X., & Wu, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135528 · Cited by 73 · see citing works

Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators

Debele, T. A., Yeh, C.-F., & Su, W. (2020) · Cancers · doi:10.3390/cancers12123773 · Cited by 85 · see citing works

B7-H3/CD276: An Emerging Cancer Immunotherapy

Zhou, W.-T., & Jin, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701006 · Cited by 295 · see citing works

pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review

Yan, Y., & Ding, H. (2020) · Nanomaterials · doi:10.3390/nano10081613 · Cited by 108 · see citing works

New opportunities for nanoparticles in cancer immunotherapy

Park, W., Heo, Y.-J., & Han, D. K. (2018) · Biomaterials Research · doi:10.1186/s40824-018-0133-y · Cited by 222 · see citing works